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Chromosome 22q11.2 deletion syndrome (22q11DS) is the most common microdeletion syndrome in humans. It is typiﬁed by
highly variable symptoms, which might be explained by epigenetic regulation of genes in the interval. Using computational
algorithms,our laboratory previously predicted that DiGeorge critical region 6(DGCR6),which lies within the deletioninterval,is
imprinted inhumans.Expression andepigenetic regulation of thisgene have not, however,been examined in22q11DS subjects.
The purpose of this study was to determine if the expression levels of DGCR6 and its duplicate copy DGCR6L in 22q11DS
subjects are associated with the parent-of-origin of the deletion and childhood psychopathologies. Our investigation showed no
evidence of parent-of-origin-related differences in expression of both DGCR6 and DGCR6L. However, we found that the
variability in DGCR6 expression was signiﬁcantly greater in 22q11DS children than in age and gender-matched control
individuals. Children with 22q11DS who had anxiety disorders had signiﬁcantly lower DGCR6 expression, especially in subjects
with the deletion on the maternal chromosome, despite the lack of imprinting. Our ﬁndings indicate that epigenetic mechanisms
other than imprinting contribute to the dysregulation of these genes and the associated childhood psychopathologies observed
in individuals with 22q11DS. Further studies are now needed to test the usefulness of DGCR6 and DGCR6L expression and
alterations in the epigenome at these loci in predicting childhood anxiety and associated adult-onset pathologies in 22q11DS
subjects.
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Introduction
Chromosome 22q11.2 deletion syndrome (22q11DS), also
knownasvelocardiofacialorDiGeorgesyndrome,isacommon
hemizygous microdeletion syndrome occurring in 1 in 1600–
4000 live births.
1 Approximately 85% of subjects carry a 3-Mb
deletion (Figure 1). A minority with a smaller 1.5-Mb deletion
stillshowallthecharacteristicsofthedisorder,delimitingthisas
the 22q11DS minimal DiGeorge critical region (DGCR).
Individuals with 22q11DS display variable conotruncal heart
defects, atypical facial features, velopharyngeal insufﬁciency,
and cognitive and psychiatric abnormalities.
2–4
The cognitive abnormalities include borderline IQ to mild
intellectual impairment, poor sustained attention, executive
dysfunction and visual–spatial skills.
5–8 Minor psychiatric
manifestations are common during childhood, with as many
as 50% experiencing an anxiety disorder and/or ADHD.
9–13 In
late adolescence and early adulthood, major psychotic
disorders, such as schizophrenia, bipolar illness and
major depression, develop in 25–40% of the affected indivi-
duals.
14–16 These cognitive and psychiatric manifestations
vary in their severity and frequency.
Moreover, differential brain effects have been reported
between 22q11DS subjects with a maternal or paternal
deletion. One magnetic resonance imaging study and another
involving the characterization of language reported that in
children with 22q11DS gray-matter volume is more reduced
andlanguagedisabilitiesaremoreseverewhenthedeletionis
on the maternal chromosome.
17,18 These ﬁndings suggest
that the parent-of-origin of the deletion may differentially
affect neurodevelopmental abnormalities. How the parental
origin of a deletion can affect gene expression and psycho-
logical outcomes in individuals with 22q11DS has not been
determined.
Genomic imprinting is a parent-of-origin-dependent epige-
netic mechanism that results in the monoallelic silencing of
genes. Epigenetic factors, such as DNA methylation and
histone modiﬁcations, result in the monoallelic silencing of
thesegenes.Monoallelic silencing notonly occursina parent-
of-origin-dependent manner, as observed in genomic imprint-
ing, but can also occur in a random parental manner.
19 This
novel form of gene regulation is necessary for appropriate
development, but it renders loci functionally haploid, thereby
increasing their vulnerability to disorders caused by both
genetic and epigenetic changes. In fact, disrupted genomic
imprinting patterns cause several clearly deﬁned syn-
dromes,
20–22 and are also implicated in complex conditions
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23 In complex disorders, like 22q11DS,
epigenetic dysregulation could similarly lead to variable
features such as age of onset, severity and parental effects.
24
Nevertheless, direct evidence for monoallelic silencing of
genes or metastable epialleles
25 in the DGCR has not yet
been demonstrated.
To explore the role that epigenetic regulation has in the
etiology of 22q11DS, one mouse study investigated the
imprintstatusof25geneswithintheDGCR andfoundthemall
to be bi-allelically expressed in developing and adult brains.
Thus, the authors concluded that imprinting or allelic biasing
could not explain the phenotypic features of 22q11DS.
26
Nevertheless, computational approaches in our laboratory
predicted that the gene DGCR6, lying in the DGCR, is
imprinted in the human,
27 but not in the mouse.
28
DGCR6 is thought to contribute to the manifestations of
22q11DS, although its exact function has not been clearly
deﬁned. It is implicated in neural crest cell migration,
29
pharyngeal arch development, and in the regulation of other
genes implicated in 22q11DS (for example, TBX-1 and
UFD1L).
30 DGCR6 is duplicated in the primate lineage
(DGCR6L), with both genes residing in the DGCR.
29 DGCR6
and DGCR6L share 97% identity at the cDNA level,
similar expression proﬁles, redundant functions and
have only seven amino-acid differences between them.
29
The duplication of DGCR6 is particularly interesting, as gene
duplication could lead to dosage compensation by random
silencing of one allele of each paralog that later could have




of one of the parental alleles on chromosome 22 directs null
expression of DGCR6/DGCR6L, as would be expected from
an imprinted gene expressed only from that allele. Our ﬁrst
hypothesis was that 22q11DS children with paternally derived
deletionswoulddemonstratenullexpression ofDGCR6asour
computational analyses had predicted that DGCR6 would be
expressed from the paternal allele.
27 Our second hypothesis
wasthat such alterationsof DGCR6 gene-expression patterns
based on parent-of-origin of the deletion would be correlated
withtheneuropsychologicalﬁndingsinchildrenwith22q11DS.
We also examined the expression of DGCR6L as it is a
duplicate of DGCR6 and thus its expression and association
with the neuropsychological ﬁndings in children with 22q11DS
could be similar. Thus, our aims were to determine the
expression patterns of DGCR6 and DGCR6L in subjects with
22q11DS compared with age- and gender-matched control
subjects. We also wanted to know whether the expression of
the two genes could be attributed to differential methylation at
their promoter regions. We further wanted to examine the
relationship between the parent-of-origin of the deletion,
expression of DGCR6/DGCR6L and neuropsychological ﬁnd-
ings in children with 22q11DS.
Materials and methods
Sample collection. Blood was collected from 38 subjects
(males¼23, females¼15; mean age¼10.4±2.6 years)
carrying a 22q11.2 microdeletion conﬁrmed by ﬂuorescent
in situ hybridization and 16 controls who were age and gender
matched to the subjects (males¼7, females¼9; mean
age¼11.6±2.0 years). Samples were obtained from the
Duke University Medical Center and Wake Forest University
Health Sciences under the protocols approved by the
Institutional Review Boards of these institutions. There were
no signiﬁcant differences in age (t statistic¼1.7, P40.05),
gender (w
2¼1.3, P40.2) and parental socio-economic status
(t statistic¼0.006, P40.9) between the two groups. Thirty-
four of the 22q11DS subjects were Caucasian, two were
African American and two were Hispanic. Of the control
subjects, eight were Caucasian and eight were African
American, resulting in a signiﬁcant difference in race
between the two groups (w
2¼15.2, Po0.001). The subjects
were all non-psychotic. A three-generation pedigree was
drawn to ascertain developmental or genetic disorders,
mental illness, learning disabilities and other cognitive
defects in the families of the 22q11DS subjects as well as
the control subjects. Personal or family histories of cognitive
defects, psychotic illness or congenital anomalies in ﬁrst-
degree relatives were used as exclusion criteria for the control
subjects. Children with 22q11DS who had an IQ o50 were
excluded from the study, as were control subjects with an IQ
4115. This minimized the intellectual disparities between the
two groups and ensured optimal performance of 22q11DS
children on the neurocognitive battery.
Determining parental origin of the 22q11.2 deletion. DNA
was extracted from the blood samples of 22q11DS subjects
and their parents (at least from one or both when available)
Figure 1 Genomic rearrangements in 22q11.2 deletion syndrome (22q11DS)
and the DiGeorge Critical Region (DGCR6)/DGCR6L locus. (a) 22q11DS patients
bear a well-deﬁned 3-Mb microdeletion at 22q11.2, mediated by low copy repeats
(LCR22s) ﬂanking the breakpoints. (b) The DGCR is a nested 1.5-Mb deletion that
exhibits all the characteristic psychological and psychiatric symptoms of the
syndrome. (c) Approximately 30 genes lie within the critical region, and some of
these that are believed to be implicated in the phenotype are shown, including
DGCR6 and its duplicate copy DGCR6L.
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Translational Psychiatryusing the Gentra Puregene Kit (Qiagen Sciences, Valencia,
CA, USA). These subjects were then genotyped for 450
single-nucleotide polymorphisms (SNPs) corresponding to
the 1.5-Mb deleted region using the iPLEX assay from
Sequenom (Sequenom, Inc., San Diego, CA, USA). SNPs were
selected using the Tagger program built into the Haploview
software for the HapMap data, which utilizes linkage
disequilibrium to identify a minimal set of SNPs for this
region. We compared parental and child genotypes across 50
unlinked SNPs spanning the 1.5-Mb DGCR interval. In
instances where only one parent was available, the parent-
of-origin could be determined with certainty when the deletion
was inherited from the parent whose genotype was available.
In subjects in whom the deletion was thought to be on the
chromosome from the unavailable parent, the hemizygous
genotypes in the subject would match those of the available
parent. A probability analysis was then performed with the
SNPs to determine the likelihood that the other parent
could have had identical genotypes across the interval; a
probability of at least 0.95 of the parent-of-origin of the
deletion was the threshold at which the determination was
made. This was the case for four of the subjects with
22q11DS. The parent-of-origin of the deletion for the rest was
easily determined.
DGCR6 and DGCR6L expression analysis. RNA was
extracted from control and subject blood samples (white
blood cells) using the PAXgene Blood RNA Kit (Qiagen
Sciences), and then reverse transcribed using oligo dT
primer and Superscript II (Invitrogen, Carlsbad, CA, USA).
The expression levels were quantiﬁed using Taqman real-
time PCR on the Applied Biosystems 7900HT Fast Real-
Time PCR System (Applied Biosystems, Carlsbad, CA,
USA). Custom-designed ABI gene expression assays for
DGCR6 (Hs00606390mH) and DGCR6L (Hs00819920mH)
were utilized, and each reaction was performed in triplicate
with b-actin as an internal control. Real-time data were
processed as reported previously to calculate the expression
relative to that of b-actin, to avoid errors related to amounts




has on DGCR6 and DGCR6L expression, parametric and
non-parametric analyses were performed. Children with
22q11DS were divided into three groups, based on the
expression of DGCR6 and DGCR6L relative to control
subjects: those showing underexpression (o2 s.e.m. of the
controls), average expression (expression within 2 s.e.m. of
the controls) or overexpression (42 s.e.m. of the controls).
Analysis of variance (ANOVA) was performed to ascertain
expression differences in the three groups. The w
2 tests were
used to determine if the distributions of low, average
and high expressers were signiﬁcantly different between the
controls, and maternally and paternally deleted 22q11DS
subjects (GraphPad Prism; GraphPad Software, La Jolla,
CA, USA).
Correlation of DGCR6 and DGCR6L expression with
methylation in 22q11DS blood samples. Genomic DNA
from 16 subjects with 22q11DS and 3 control subjects’ blood
samples were bisulﬁte treated as reported previously.
33
Primers were designed to amplify bisulﬁte-treated DNA
in the promoter regions of DGCR6 and DGCR6L
(Supplementary Table 1) using Epidesigner-beta (http://
www.epidesigner.com) from Sequenom (Sequenom, Inc.).
Primer speciﬁcity was checked by BLAST against the entire
bisulﬁte-treated genome (http://bisearch.enzim.hu). Regions
were PCR-ampliﬁed and methylation was quantiﬁed using the
Sequenom Massarray system (Sequenom).
34,35 The results
were analyzed using Sequenom’s Epityper software and
statistical tests were done using repeated-measures ANOVA,
with multiple CpG sites being evaluated.
Association of DGCR6 and DGCR6L expressions with
neuropsychological data. Neuropsychological data were
collected from the subjects and controls. Assessments
were made for vigilance/attention, verbal learning and
reasoning, and executive function based on task-force
recommendations developed by the NIMH Measurement
and Treatment Research to Improve Cognition in Schizo-
phrenia (MATRICS).
36 Executive function was measured with
the Wisconsin Card Sort Test (WCST), which involves
matching of cue cards containing different shapes and
colors.
37 Sustained attention was assessed with the identi-
cal pairs and AX conditions of the continuous perfor-
mance test, which are based on recognition of identical
numbers and a pattern of numbers, respectively.
38,39
In addition, the California verbal learning test
40 was used
to assess verbal learning and memory. The Wechsler
Intelligence Scale for children (WISC) was used for
intelligence testing. The computerized diagnostic inter-
view schedule for children was administered to ascertain
psychiatric disorders, such as anxiety, based on DSM-IV
criteria.
Statistical analyses were performed using the SPSS
Version 18.0 (SPSS, Chicago, IL, USA). Independent
two-sample t-tests and ANOVA were performed to evaluate
group differences on continuous variables and Fisher’s
exact test and w
2 for categorical variables. Pearson
correlations were performed to assess associations bet-
ween the psychological and gene-expression data. All of our
analyses were performed on the basis of a priori hypotheses.
Thus, we did not correct for multiple testing, an approach




Parental origin of 22q11.2 deletion. Parental genotypes
were available in 35/38 subjects with 22q11DS. Of these, 22
deletions were present on the maternal chromosome while
13 were on the paternal chromosome. One child with
22q11DS had an inherited deletion of the 22q11.2 region
from his mother; the others were de novo deletions.
Complete psychological data as well as gene-expression
data were available for 19 subjects with a maternal deletion
and 11 subjects with a paternal deletion. Correlational
analyses with the neuropsychological data were performed
with this subset of patients.
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Translational PsychiatryDGCR6 and DGCR6L expression. DGCR6 and DGCR6L
expressions were highly correlated in the 22q11DS subjects
(r¼0.9; Po0.01) and controls (r¼0.9; Po0.01). There were
no signiﬁcant differences in expression of both DGCR6 and
DGCR6L between the 22q11DS and control groups. The
average relative expression of DGCR6 for 22q11DS subjects
was 1.7±0.3 (mean and s.e.m.) (n¼38) while that in
controls was 1.2±0.2 (n¼16) (F¼1.07, P¼not signiﬁcant,
Cohen’s d¼0.4). The average relative expression of
DGCR6L for 22q11DS subjects was 1.5±0.2 (n¼38) while
that in controls was 1.2±0.2 (n¼16) (F¼0.677, P¼not
signiﬁcant, Cohen’s d¼0.3). However, the variability of
DGCR6 expression was signiﬁcantly greater among the
subjects with 22q11DS than in the controls (Levene’s test for
homogeneity of variance, F¼7.68, Po0.05). DGCR6
expression did not vary signiﬁcantly between the control
subjects (1.2±0.2) and 22q11DS subjects with maternal
(2.0±0.4) and paternal deletions (1.4±0.6) (F¼1.00,
P¼not signiﬁcant). Similarly, for DGCR6L, there were no
differences in expression between controls (1.2±0.2),
maternal (1.5±0.3) and paternal deletions (1.4±.3)
F¼0.40, P¼not signiﬁcant. When we trichotomized the
22q11DS subjects into normal, high and low expressers
based on their expressions relative to controls, as described
in the methods (Figures 2a and b), we found that for DGCR6
expression there was a trend toward more high and low
expressers in the 22q11DS subjects with a maternally
derived deletion (w
2¼8.45, P¼0.07). The distribution of
high, low and average expressers was not signiﬁcant for
DGCR6L (w
2¼3.0, P40.05).
As there was a signiﬁcant difference in race in the control
group and the 22q11DS group, with half the control group
being African American, we looked for differences in expres-
sion in the Caucasian controls compared with the African-
American controls and there were no signiﬁcant differences
for DGCR6 (F¼0.008, P40.05) and DGCR6L (F¼0.136,
P40.05). Thus, we did not covary for race in further analyses.
DGCR6 and DGCR6L promoter methylation levels in
22q11DS subjects. We compared the DNA methylation
levels at the promoter regions of DGCR6 and DGCR6L
in 16 22q11DS subjects, which included eight maternally
and eight paternally deleted subjects; three controls were
also investigated. As the expense associated with the
methylation analyses were prohibitive, we selected a
representative set of maternal and paternally deleted
subjects with 22q11DS and control subjects for this
analyses. We observed that this region was primarily
unmethylated in all controls and subjects, regardless of the
parental origin of the deletion. The average methylation
across 16 CpG sites at  284 to  122 upstream of the
DGCR6 promoter was 3.1±1.7% for maternally deleted
subjects, 3.1±1.6% for paternally deleted subjects and
2.2±1.9% for controls (ANOVA, P40.05, F¼0.66). The
average methylation across 50 CpG sites at þ206 to  772
bp upstream of the DGCR6L promoter was 7.5±1.3% for
maternally deleted subjects, 8.0±1.8% for paternally deleted
subjects and 6.2±1.9% for controls (ANOVA, P40.05,
F¼0.85).
Relationship between DGCR6 and DGCR6L expression
and neuropsychological symptoms. Consistent with our
previous report, the subjects with 22q11DS performed worse
than the control subjects on all the psychological tests.
6,11 In
the 22q11DS group, DGCR6 expression was signiﬁcantly
lower (F¼5.42, Po0.05) in those with anxiety disorders
(n¼17/37) (Table 1). Similarly, the maternally deleted
subjects with an anxiety disorder (n¼6/19) showed a
signiﬁcantly lower expression of both DGCR6 (F¼7.8,
Po0.01) and DGCR6L (F¼5.37, Po0.05) (Table 2). This
signiﬁcant difference in the expression levels was not present
in the paternally deleted subjects or the control subjects.
Upon dividing the 22q11 subjects into low, average and high
expressers, there was a signiﬁcantly higher incidence of
anxiety disorders in the low expressers (w
2¼6.55, Po0.05).
Higher internalizing behaviors, which are indicative of
anxiety, were also signiﬁcantly correlated with lower
expression of DGCR6L (Table 1). No such relationships
between the level of expression and anxiety disorders were
seen in the control subjects.
Discussion
22q11DS is characterized by a multitude of neuropsycholo-
gical abnormalities.
3 Two studies reported that maternal
inheritance of the deletion was associated with a greater
reduction in cortical gray matter and increased language-
learning disabilities.
17,18 This parental effect suggested a
possible role for epigenetic regulation, such as genomic
imprinting. Although mouse studies ruled out parent-of-origin-
speciﬁc expression of the 25 genes lying within the 22q11DS
critical region,
26 computational analysis in our laboratory
predicted DGCR6 to be monoallelically expressed in humans,
with expression from the paternal allele.
27 It was not predicted
tobeimprintedinmice.
28DGCR6isbelievedtoberequiredfor
neural crest cell migration during development
30 and
GABAB-receptor localization.
42 It is also linked to schizo-
phrenia susceptibility in completely independent association
studies.
43 Thus, we postulated that DGCR6 could be
imprinted and that functional dysregulation of DGCR6 would
be correlated with the psychological abnormalities observed
in subjects with 22q11DS, wherein one allele is deleted.
We ﬁrst compared the expression levels of DGCR6 and its
duplicate copy DGCR6L between 22q11DS subjects with
maternal and paternal 22q11.2 deletions, as well as with
normal age- and sex-matched controls. Contrary to the
expectations based on the expected hemizygous state of
DGCR6andDGCR6Lin22q11DSsubjects,alargenumberof
22q11DS subjects showed dysregulated rather than reduced/
null-geneexpression when compared with thosein the control
individuals. This ﬁnding excludes the possibility of genomic
imprinting of these genes in peripheral blood, wherein all
subjects deleted from one particular parental allele would be
expected to have null expression. It is, however, possible that
imprinting could occur in other tissues that were not examined
in this study. There were three groups that could be
distinguished in the 22q11DS subjects; those with DGCR6
and DGCR6L expression levels markedly lower than controls,
those with the expression levels similar to the controls and the
individuals who exhibited gross overexpression of the genes.
DGCR6 and DGCR6L expression in 22q11DS syndrome
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Translational PsychiatryOne possible explanation for the dysregulated expression of
DGCR6 and DGCR6L in children with 22q11DS is that the
other epigenetically regulated imprinted genes residing in the
22q11DS interval on the intact chromosome 22 could
inﬂuence the expression of DGCR6 and DGCR6L in the
affected individuals. Other deleted genes are also likely to
contribute to the psychopathological manifestations of
22q11DS, as this is a contiguous microdeletion syndrome.
44
Thus, it is now critical to determine the imprint status of all the
genes in the human that reside in the 22q11DS minimum-
deleted region.
We also observed a signiﬁcant relationship between the
increased frequency ofanxiety disorders and low DGCR6 and
DGCR6L expression in children with 22q11DS. Additionally,
we found moderate correlations between low expression level
and higher parent ratings of internalizing symptoms, which is
an indirect indicator of anxiety symptoms. The importance of
this observation is strengthened further by the observation
that when analyses were performed after dividing the 22q11
subjects into low, average and high expressers, there was a
signiﬁcantly higher incidence of anxiety disorders in the low
expressers. The association between childhood anxiety
Figure 2 Relative gene expression of human DiGeorge Critical Region (DGCR6) (a) and DGCR6L (b). The fold expression levels relative to the average mean of the
controls are displayed for controls (yellow), 22q11DS subjects with paternal deletions (blue) and 22q11DS subjects with maternal deletions (pink). The average relative
expression level of each group is marked with a dashed line.
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Translational Psychiatrydisorders, broader internalizing symptoms and DGCR6
expression may have implications for psychosis risk later in
life, as 40–60% of children with 22q11DS have high levels of
anxiety in childhood, and anxiety disorders are frequently
seen in association with psychotic conditions such as
schizophrenia.
45 Most recently, the DGCR6 protein was
shown to interact with GABAB receptor subunit, GABAB1,
and aid its localization to the endoplasmic reticulum.
42 This
ﬁnding is intriguing as the GABAB receptor may be involved in
schizophrenia.Infact,completelyindependentgeneticlinkage
studies implicate DGCR6 in schizophrenia susceptibility.
43,46
Prospective psychological/psychiatric follow-up studies in our
cohort are underway and will help determine the relationship
between anxiety, psychosis, and DGCR6 and DGCR6L
expression. The correlation between DGCR6 and DGCR6L
expression and neurocognition must also be further investi-
gated as 22q11DS subjects with lower sustained attention
scores tended to have a higher expression of DGCR6.
Impaired sustained attention is an integral part of the
neurocognitive phenotype in 22q11DS.
11 Additionally, im-
paired sustained attention is a hallmark of schizophrenia, with
the22q11DSsubjectsshowingdecreasedsustainedattention
with the onset of schizophrenia.
47
In order to explain the dysregulated expression pattern of
DGCR6 and DGCR6L in subjects with 22q11DS, we
determined the level of DNA methylation of the promoters in
both the 22q11DS and control individuals. We found the
promoter regions to be unmethylated in all the cases.
Nevertheless, it is likely there are epigenetic control regions
at other genomic locations that regulate the expression of
these genes, resulting in the variability of DGCR6 and
DGCR6L expression that we found in the 22q11DS group.
Our ﬁndings indicate that DNA methylation and histone
modiﬁcations need to be mapped for the entire minimum-




The limitation of this study is its small sample size.
However, owing to the difﬁculty in ascertaining affected
individuals with 22q11DS and obtaining the samples and
measures required for a study as this, our sample size would
notbeunusuallysmall.Anotherlimitationisthatwedidnotuse
a correction for multiple comparisons, such as a Bonferroni,
although we chose all of our measures based on a priori
hypotheses.
In conclusion, our investigations reveal that low expression
levels of the vital genes DGCR6 and DGCR6L are associated
with the observed variability in anxiety disorders in children
with 22q11DS. This expression pattern could serve as a
biomarker to predict anxiety and the development of
associated schizophrenia if further studies conﬁrm our
ﬁndings. We also show here that expression of these genes
is likely controlled by complex epigenetic mechanisms that
when disrupted lead to dosage aberration, rather than simple
reduction in gene expression, and the variability in symptoms
seen in individuals with 22q11DS. Understanding their
regulation and function directly in humans will be the key to
understanding the role of epigenetics in complex disorders
such as 22q11DS. Such knowledge could also prove to be of
value in predicting those subjects who will develop psycho-
pathologies and in developing novel therapies based on
modifying the epigenome.
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medium¼0.25 and large¼0.40 for ANOVA). Pearson’s correlations were
computed for all variables, except for anxiety disorders, wherein ANOVA was
computed, to examine differences in expression of DGCR6 and DGCR6L in
those with and without an anxiety disorder.
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